The oncologistJanuary 17, 2025Cristiane Decat Bergerot, Paulo Gustavo Bergerot, Errol J Philip et al.4 citations
Patients with metastatic renal cell carcinoma (mRCC) experience emotional distress and limited supportive care access. This study assesses a mindfulness app's feasibility, acceptability, and preliminary efficacy in improving emotional symptoms, trait mindfulness, and overall quality of life for patients with mRCC on immunotherapy. This multinational study recruited patients with mRCC undergoing...
Different study designs of psychedelic trials may impact the blinding and expectance, leading to biased treatment effects. This study aimed to examine the association between antidepressant efficacy and study designs in psychedelic trials. Six databases were systematically searched. Eligible trials were required to investigate the efficacy of psychedelics (psilocybin, lysergic acid diethylamide...
MDMA or 3,4- methylenedioxymethamphetamine is a psychoactive substance, exhibiting mild hallucinogenic properties, that became widely known as a recreational party drug. However, its ability in helping individuals access deeply rooted emotions has prompted significant interest in its potential applications within clinical practice. MDMA’s mechanism of action involves increasing the release of...
During most dreams, the dreamer does not realize that they are in a dream. In contrast, lucid dreaming allows to become aware of the current state of mind, often accompanied by considerable control over the ongoing dream episode. Lucid dreams can happen spontaneously or be induced through diverse behavioural, cognitive or technological strategies. Such induction techniques have spurred research...
Ketamine, a dissociative compound, shows promise in treating mood disorders, including treatment-resistant depression (TRD) and bipolar disorder (BD). Despite its therapeutic potential, the neurophysiological mechanisms underlying ketamine's effects are not fully understood. This study explored acute neurophysiological changes induced by subanesthetic doses of ketamine in BD patients with...
Current research on psychedelic-assisted therapy (PAT) focuses on their potential to treat clinical psychiatric conditions such as treatment-resistant depression, anxiety, and PTSD. Presumably, if ...
NMDAR antagonists, such as memantine and ketamine, have shown efficacy in treating neurodegenerative diseases and major depression. The mechanism by which these drugs correct the aforementioned diseases is still unknown. Our study reveals that these antagonists significantly enhance 20S proteasome activity, crucial for degrading intrinsically disordered, oxidatively damaged, or misfolded...
Results of new psychedelic research aimed at patients with severe treatment resistant depression (TRD) found significant decreases in their depressive symptoms. Researchers of the open‐label study also found significant safety and efficacy of synthetic psilocybin in TRD patients.
Intranasal esketamine, approved with oral antidepressants for adults with treatment-resistant depression (TRD), is the S-enantiomer of ketamine and has higher potency and affinity for N-Methyl-d-Aspartate receptors. Administered intranasally, it offers rapid absorption and onset, essential for severe depressive symptoms or suicidal impulses. Comparative studies on esketamine and ketamine's...
Interest in mindfulness is growing within the Muslim community, as many individuals are integrating it into their daily lives to enhance their spiritual journey and overall well-being. Despite limited Arabic research on mindfulness, none, to the researcher’s knowledge, have provided a theoretical framework for mindfulness in Islam. Therefore, the current study aims to establish such a framework...